Antonio J. Gallo

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Journal: Annales d'endocrinologie

Published: May 08, 2026

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions.

Journal: Annales d'endocrinologie

Published: March 21, 2026

Advancing Retinal Imaging for Cardiovascular Risk Assessment.

Advancing Retinal Imaging for Cardiovascular Risk Assessment.

Journal: JAMA cardiology

Published: March 18, 2026

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC).

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC).

Journal: Annales d'endocrinologie

Published: February 17, 2026

Lipoprotein(a) Levels and Epicardial Adipose Tissue Volume in patients living with Diabetes: a discordant relationship. An observational study.

Lipoprotein(a) Levels and Epicardial Adipose Tissue Volume in patients living with Diabetes: a discordant relationship. An observational study.

Journal: European journal of preventive cardiology

Published: February 14, 2026

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

Journal: Archives of cardiovascular diseases

Published: February 06, 2026

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC).

Journal: Diabetes & metabolism

Published: January 09, 2026

From LDL to ApoB: shifting the lens on cardiovascular risk.

From LDL to ApoB: shifting the lens on cardiovascular risk.

Journal: European journal of preventive cardiology

Published: November 16, 2025

Homozygous familial hypercholesterolemia: New therapeutic approach and a call for action!

Homozygous familial hypercholesterolemia: New therapeutic approach and a call for action!

Journal: Archives of cardiovascular diseases

Published: August 04, 2025

Remnant cholesterol: a promising target besides LDLc for cardiovascular risk reduction?

Remnant cholesterol: a promising target besides LDLc for cardiovascular risk reduction?

Journal: European journal of preventive cardiology

Published: July 30, 2025

Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.

Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.

Journal: Molecular metabolism

Published: June 10, 2025

Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia.

Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia.

Journal: Journal of clinical lipidology

Published: June 04, 2025

Showing 1-12 of 105

Last Updated: 09/26/2026